Cross-sectional and longitudinal relationships between cerebrospinal fluid biomarkers and cognitive function in people without cognitive impairment from across the adult life span

JAMA Neurology

Volumn 71, Issue 6, 2014, Pages 742-751

  Li, Ge ^a   Millard, Steven P ^b   Peskind, Elaine R ^a,b   Zhang, Jing ^a   Yu, Chang En ^a,c   Leverenz, James B ^a,d   Mayer, Cynthia ^b   Shofer, Jane S ^a   Raskind, Murray A ^a,b   Quinn, Joseph F ^e,f   Galasko, Douglas R ^g   Montine, Thomas J ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b VA PUGET SOUND HEALTH CARE SYSTEM   (United States)

^c GERIATRIC RESEARCH EDUCATION AND CLINICAL CENTER   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

^e OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^f Medical Education   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; APOLIPOPROTEIN E; BIOLOGICAL MARKER; ISOPROSTANE DERIVATIVE; TAU PROTEIN;

ADULT; AGE; AGED; APOLIPOPROTEIN E GENE; ARTICLE; CEREBROSPINAL FLUID ANALYSIS; COGNITION; CROSS-SECTIONAL STUDY; EDUCATIONAL STATUS; EXECUTIVE FUNCTION; FEMALE; HUMAN; LONGITUDINAL STUDY; MALE; MENTAL PERFORMANCE; NEUROPSYCHOLOGICAL TEST; NORMAL HUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RECALL;

ADULT; AGED; AGED, 80 AND OVER; AGING; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; BIOLOGICAL MARKERS; COGNITION DISORDERS; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; TAU PROTEINS;

EID: 84902180105     PISSN: 21686149     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamaneurol.2014.445     Document Type: Article

References (46)

1. Herndon JG, Moss MB, Rosene DL, Killiany RJ. Patterns of cognitive decline in aged rhesus monkeys. Behav Brain Res. 1997;87(1):25-34 (Pubitemid 27421546)
2. Buckner RL. Memory and executive function in aging and AD: multiple factors that cause decline and reserve factors that compensate. Neuron. 2004;44(1):195-208 (Pubitemid 39348840)
3. Negash S, Bennett DA,Wilson RS, Schneider JA, Arnold SE. Cognition and neuropathology in aging: multidimensional perspectives from the Rush Religious Orders Study and Rush Memory and Aging Project. Curr Alzheimer Res. 2011;8(4): 336-340
4. Gelber RP, Launer LJ, White LR. The Honolulu-Asia Aging Study: epidemiologic and neuropathologic research on cognitive impairment. Curr Alzheimer Res. 2012;9(6):664-672
5. Montine TJ, Sonnen JA, Montine KS, Crane PK, Larson EB. Adult Changes in Thought study: dementia is an individually varying convergent syndrome with prevalent clinically silent diseases that may be modified by some commonly used therapeutics. Curr Alzheimer Res. 2012;9(6): 718-723
6. Rabinovici GD, JagustWJ. Amyloid imaging in aging and dementia: testing the amyloid hypothesis in vivo. Behav Neurol. 2009;21(1):117-128
7. Roe CM, Fagan AM, Grant EA, et al. Amyloid imaging and CSF biomarkers in predicting cognitive impairment up to 7.5 years later. Neurology. 2013; 80(19):1784-1791
8. Bateman RJ, Xiong C, Benzinger TL, et al Dominantly Inherited Alzheimer Network. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med. 2012;367(9): 795-804
9. Lo RY, JagustWJ; Alzheimer's Disease Neuroimaging Initiative. Vascular burden and Alzheimer disease pathologic progression. Neurology. 2012;79(13):1349-1355
10. LongstrethWT Jr, Sonnen JA, Koepsell TD, KukullWA, Larson EB, Montine TJ. Associations between microinfarcts and other macroscopic vascular findings on neuropathologic examination in 2 databases. Alzheimer Dis Assoc Disord. 2009; 23(3):291-294
11. Sonnen JA, Breitner JC, Lovell MA, Markesbery WR, Quinn JF, Montine TJ. Free radical-mediated damage to brain in Alzheimer's disease and its transgenic mouse models. Free Radic Biol Med. 2008;45(3):219-230
12. Bayer-Carter JL, Green PS, Montine TJ, et al. Diet intervention and cerebrospinal fluid biomarkers in amnestic mild cognitive impairment. Arch Neurol. 2011;68(6):743-752
13. BrysM, Pirraglia E, Rich K, et al. Prediction and longitudinal study of CSF biomarkers in mild cognitive impairment. Neurobiol Aging. 2009;30 (5):682-690
14. Seet RC, Lee CY, Chan BP, et al. Oxidative damage in ischemic stroke revealed using multiple biomarkers. Stroke. 2011;42(8):2326-2329
15. 42 ratio for increased risk ofmild cognitive impairment: a follow-up study. Neurology. 2007;69(7):631-639 (Pubitemid 47256004)
16. Peskind ER, Riekse R, Quinn JF, et al. Safety and acceptability of the research lumbar puncture. Alzheimer Dis Assoc Disord. 2005;19(4):220-225 (Pubitemid 44366623)
17. Dumurgier J, Vercruysse O, Paquet C, et al. Intersite variability of CSF Alzheimer's disease biomarkers in clinical setting. Alzheimers Dement. 2013;9(4):406-413
18. Mattsson N, Andreasson U, Persson S, et al. The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers. Alzheimers Dement. 2011;7(4):386-395.e386. doi:10.1016/j.jalz.2011.05.2243
19. Milatovic D, VanRollinsM, Li K, Montine KS, Montine TJ. Suppression of murine cerebral F2-isoprostanes and F4-neuroprostanes from excitotoxicity and innate immune response in vivo by α- or γ-tocopherol. J Chromatogr B Analyt Technol Biomed Life Sci. 2005;827(1):88-93 (Pubitemid 41551601)
20. Hixson JE, Vernier DT. Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. J Lipid Res. 1990;31(3): 545-548 (Pubitemid 20107994)
21. Wechsler D.Wechsler Memory Scale-Revised. New York, NY: Harcourt Brace Jovanovich; 1987
22. Gomez RG, White DA. Using verbal fluency to detect very mild dementia of the Alzheimer type. Arch Clin Neuropsychol. 2006;21(8):771-775 (Pubitemid 44693170)
23. Reitan RWD. The Halstead-Reitan Neuropsychological Test Battery. Tucson, AZ: Neuropsychology Press; 1985
24. Pinheiro J, Bates D. Mixed-Effects and Models in S and S-PLUS. New York, NY: Springer; 2000
25. Nakagawa S, Schielzeth H. A general and simple method for obtaining R2 from generalized linear mixed-effects models. Methods Ecol Evol. 2013;4 (2):133-142
26. Kronmal RA. Spurious correlation and the fallacy of the ratio standard revisited. J R Stat Soc Ser A Stat Soc. 1993;156(3):379-392
27. Shaw LM, Vanderstichele H, Knapik-Czajka M, et al Alzheimer's Disease Neuroimaging Initiative. Cerebrospinal fluid biomarker signature in Alzheimer's Disease Neuroimaging Initiative subjects. Ann Neurol. 2009;65(4):403-413
28. Milliken JK, Edland SD.Mixed effect models of longitudinal Alzheimer's disease data: a cautionary note. Stat Med. 2000;19(11-12):1617-1629 (Pubitemid 30346251)
29. Holm S. A simple sequential rejective multiple test procedure. Scand J Stat. 1979;6:65-70
30. R Development Core Team. R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing; 2012
31. Pinheiro J, DebRoy S, Sarkar D; R Core Team. nlme: Linear and Nonlinear Mixed Effects Models, R package, Version 3.1-104. Vienna, Austria: R Foundation for Statistical Computing; 2012
32. Bates D, Maechler M, Bolker B,Walker S. Lme4: linear mixed-effects models using Eigen and S4. R package, version 1.0-5. http://CRAN.Rproject.org /package=lme4. 2013. Accessed February 14, 2014
33. Vos SJ, Xiong C, Visser PJ, et al. Preclinical Alzheimer's disease and its outcome: a longitudinal cohort study. Lancet Neurol. 2013;12(10):957-965
34. Rolstad S, Berg AI, Bjerke M, Johansson B, Zetterberg H,Wallin A. Cerebrospinal fluid biomarkers mirror rate of cognitive decline. J Alzheimers Dis. 2013;34(4):949-956
35. Roe CM, Fagan AM, Grant EA, et al. Cerebrospinal fluid biomarkers, education, brain volume, and future cognition. Arch Neurol. 2011;68 (9):1145-1151
36. Fagan AM, Roe CM, Xiong C,MintunMA, Morris JC, Holtzman DM. Cerebrospinal fluid tau/β-amyloid42 ratio as a prediction of cognitive decline in nondemented older adults. Arch Neurol. 2007;64(3):343-349 (Pubitemid 46425688)
37. Duits FH, Kester MI, Scheffer PG, et al. Increase in cerebrospinal fluid F2-isoprostanes is related to cognitive decline in APOE ε4 carriers. J Alzheimers Dis. 2013;36(3):563-570
38. Ewers M, Insel P, JagustWJ, et al Alzheimer's Disease Neuroimaging Initiative (ADNI). CSF biomarker and PIB-PET-derived β-amyloid signature predictsmetabolic, gray matter, and cognitive changes in nondemented subjects. Cereb Cortex. 2012;22(9):1993-2004
39. Stomrud E, Hansson O, Zetterberg H, Blennow K,Minthon L, Londos E. Correlation of longitudinal cerebrospinal fluid biomarkers with cognitive decline in healthy older adults. Arch Neurol. 2010;67(2):217-223
40. Rolstad S, Berg AI, Bjerke M, et al. Amyloid-β42 is associated with cognitive impairment in healthy elderly and subjective cognitive impairment. J Alzheimers Dis. 2011;26(1):135-142
41. Ewers M, Insel PS, Stern Y,WeinerMW; Alzheimer's Disease Neuroimaging Initiative (ADNI). Cognitive reserve associated with FDG-PET in preclinical Alzheimer disease. Neurology. 2013; 80(13):1194-1201
42. Reiman EM, Quiroz YT, Fleisher AS, et al. Brain imaging and fluid biomarker analysis in young adults at genetic risk for autosomal dominant Alzheimer's disease in the presenilin 1 E280A kindred: a case-control study. Lancet Neurol. 2012;11 (12):1048-1056
43. Vos SJ, van Rossum IA, Verhey F, et al. Prediction of Alzheimer disease in subjects with amnestic and nonamnestic MCI. Neurology. 2013; 80(12):1124-1132
44. Ryberg C, Rostrup E, Paulson OB, et al; LADIS study group. Corpus callosum atrophy as a predictor of age-related cognitive and motor impairment: a 3-year follow-up of the LADIS study cohort. J Neurol Sci. 2011;307(1-2):100-105
45. Verdelho A, Madureira S, Moleiro C, et al LADIS Study. White matter changes and diabetes predict cognitive decline in the elderly: the LADIS Study. Neurology. 2010;75(2):160-167
46. Haight TJ, Landau SM, Carmichael O, Schwarz C, DeCarli C, JagustWJ; Alzheimer's Disease Neuroimaging Initiative. Dissociable effects of Alzheimer disease and white matter hyperintensities on brain metabolism. JAMA Neurol. 2013;70(8): 1039-1045.